Nektar Therapeutics(FRA) ITH0

Market Cap€2.13B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€61.58

-2.19%

-1.38Today

Nektar Therapeutics Financials at a Glance

Market Cap

€2.13B

Revenue (TTM)

€46.82

Net Income (TTM)

-€134.71

EPS (TTM)

-€5.74

P/E Ratio

-10.86

Dividend

€0.00

Beta (Volatility)

0.04 (Low)

Dividend

€0.00

Beta (Volatility)

0.04 (Low)

Price

€61.58

Volume

Open

€61.58

Price

€61.58

Volume

Open

€61.58

Previous Close

€61.58

Daily Range

€61.58 - €61.58

52-Week Range

€24.20 - €90.68

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.04 (Low)

Price

€61.58

Volume

Open

€61.58

Previous Close

€61.58

Daily Range

€61.58 - €61.58

52-Week Range

€24.20 - €90.68

Estimated Earnings Date

N/A

ITH0 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Howard W. Robin

Website

www.nektar.com

ITH0 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-35.02%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-9.21%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€2.13B

Shares Outstanding

34.14M

Volume

Avg. Volume

17.167

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Nektar Therapeutics Performance Analysis

Nektar Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 87,590,152	1.6%
2023	2023-12-31	EUR 83,360,188	-4.8%
2024	2024-12-31	EUR 90,993,659	9.2%
2025	2025-12-31	EUR 48,939,464	-46.2%

Nektar Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -28.08	-22.6%
2023	2023-12-31	EUR -20.16	-28.2%
2024	2024-12-31	EUR -8.02	-60.2%
2025	2025-12-31	EUR -8.62	7.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€8.71

+0.9%

Gross Profit

€8.58

+0.9%

Gross Margin

98.46%

+1.0%

Market Cap

€2.13B

N/A

Market Cap/Employee

€32.77

N/A

Employees

N/A

Net Income

-€34.94

+1.0%

EBITDA

-€35.78

+1.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€153.10

-10.9%

Total Debt

€118.90

+0.8%

Accounts Receivable

€0.00

N/A

Inventory

€0.00

N/A

Long Term Debt

€99.04

+0.8%

Short Term Debt

€19.86

+1.1%

Return on Assets

-23.75%

+0.5%

Return on Invested Capital

-64.73%

N/A

Free Cash Flow

-€65.48

+1.8%

Operating Cash Flow

-€65.40

+1.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About ITH0

What is the current price of Nektar Therapeutics?

Nektar Therapeutics is trading at €61.58 per share.

What is the 52-week range for Nektar Therapeutics?

Over the past 52 weeks, Nektar Therapeutics has traded between €24.20 and €90.68.

How much debt does Nektar Therapeutics have?

As of the most recent reporting period, Nektar Therapeutics reported total debt of €118.90M.

How much cash does Nektar Therapeutics have on hand?

Nektar Therapeutics reported €34.21M in cash and cash equivalents in its most recent financial results.

What is Nektar Therapeutics’s dividend yield?

Nektar Therapeutics does not currently have a dividend yield.

Nektar Therapeutics(FRA) ITH0

Nektar Therapeutics Financials at a Glance

ITH0 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nektar Therapeutics

ITH0 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nektar Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ITH0

What is the current price of Nektar Therapeutics?

What is the 52-week range for Nektar Therapeutics?

How much debt does Nektar Therapeutics have?

How much cash does Nektar Therapeutics have on hand?

What is Nektar Therapeutics’s dividend yield?

Premium Investing Services